RxDoctor Payments Data

Xinqi Xu, MD

Family Medicine · Elmhurst, NYNPI 1245364710

Payments from drug & device makers

$836in general payments, 2019–2025

Across 38 payments — averaging $22.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$333
  • Asahi Intecc USA, Inc.$172
  • Amarin Pharma, Inc.$119
  • Sanofi Pasteur Inc.$43
  • Gilead$39
  • Astellas Pharma US Inc$31
  • plus $99 from 5 others

What the payments were for

  • Food & beverage$83099%
  • Education$61%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$836 in reported general payments places this provider in the 60th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$48,327
Medicare patients
85
Services billed
767

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol69$82,446
JanuviaSitagliptin Phosphate80$81,973
JanumetSitagliptin Phos/Metformin Hcl67$74,672
JardianceEmpagliflozin46$58,252
OzempicSemaglutide32$47,934
VascepaIcosapent Ethyl96$33,686
TrulicityDulaglutide24$31,407
Janumet XrSitagliptin Phos/Metformin Hcl28$23,096
ProliaDenosumab14$22,478
Diclofenac Epolamine30$20,964
RestasisCyclosporine15$14,538
EliquisApixaban18$12,765
Breo ElliptaFluticasone/Vilanterol19$10,756
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$9,178
Levemir FlexpenInsulin Detemir12$4,978

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$333$82,44669 claims
Boehringer IngelheimJardiance$21$58,25246 claims
AmgenProlia$31$22,47814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,321 family medicine providers in New York.

Other family medicine in Elmhurst

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →